Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04101669 · ClinicalTrials.gov registry record · NA

RESET System Pivotal Trial (Rev F)

A NA study of Obesity and Diabetes Type 2, sponsored by Morphic Medical.

Recruiting
Registry status
NA
Development phase
264
Enrollment target
7
Study locations

NCT04101669: Recruiting NA study of Obesity and Diabetes Type 2, sponsored by Morphic Medical.

NCT04101669 is a NA study of Obesity and Diabetes Type 2 that is actively recruiting participants, run by Morphic Medical. The registered enrollment target is 264 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (68% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04101669, a NA study of Obesity and Diabetes Type 2, is actively recruiting participants, sponsored by Morphic Medical.

RECRUITING
Registry status
NA
Development phase
264 participants
Enrollment target
7
Study locations

Study Summary

A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the RESET System for Glycemic Improvement in Patients with Inadequately Controlled Type 2 Diabetes and Obesity, the STEP-1 Study. A multi-center, double-blinded, randomized, sham-controlled trial to evaluate the safety and effectiveness of the RESET System plus moderate intensity lifestyle and dietary counseling compliant with 2024 ADA Standard of Care as compared to a sham control receiving moderate intensity lifestyle and dietary counseling. Both the treatment and sham group will practice medical management compliant with STEP-1 Study Guidelines. Patients will be randomized 3 (RESET):1 (Sham).

Primary Outcome

Change in HbA1c value from baseline to 9 months.

Conditions Studied

Interventions

  • DEVICE RESET Liner
  • OTHER Sham

Study Locations (7)

District of Columbia

  • MedStar Health Research Institute - Washington D.C.

Florida

  • University of Miami Hospital - Miami

Massachusetts

  • Brigham and Women's Hospital - Boston

Michigan

  • Michigan Medicine, Division of Gastroenterology and Hepatology - Ann Arbor

New York

  • Weill Cornell Medicine - New York

Ohio

  • Cleveland Clinic - Cleveland

Texas

  • Baylor College of Medicine - Houston

Trial Details

FieldValue
Enrollment Target 264 participants
Start Date 2019-09-09
Est. Completion 2026-12-01
Phase NA
Morphic Medical

3 total trials

What NCT04101669 shows while recruiting

NCT04101669 is an interventional study that assigns participants to a tested intervention. The registered 264 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (68% lower).

The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which RESET Liner is the first listed.

NCT04101669 lists 7 locations in 7 states (District of Columbia, Florida, Massachusetts).

Frequently Asked Questions

What is clinical trial NCT04101669 about?

NCT04101669 is a clinical study titled "RESET System Pivotal Trial (Rev F)". A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the RESET System for Glycemic Improvement in Patients with Inadequately Controlled Type 2 Diabetes and Obesity, the STEP-1 Study. A multi-center, double-blinded, randomized, sham-controlled trial to evaluate the safety and eff...

What is the current status of trial NCT04101669?

This trial is currently recruiting. It is a NA study. The enrollment target is 264 participants. The study started on 2019-09-09. Estimated completion is 2026-12-01.

What conditions does trial NCT04101669 study?

This clinical trial studies the following conditions: Obesity, Diabetes Type 2.

What interventions are being tested in trial NCT04101669?

The interventions under investigation include: RESET Liner (DEVICE), Sham (OTHER).

Who is sponsoring clinical trial NCT04101669?

This trial is sponsored by Morphic Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04101669 being conducted?

This trial has 7 study locations across District of Columbia, Florida, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04101669's enrollment target sits among peer trials

264 246th of 1053 higher than 807 of 1,053 other Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04295863 · 264 participants · Phase 1

    Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers

  • NCT05220202 · 264 participants · NA

    MOTIVATE to Improve Outcomes for Older Veterans With Musculoskeletal Pain and Depression

  • NCT05473013 · 264 participants · NA

    Optimizing Digital Health Technology Interventions to Increase Skill Acquisition and Utilization

  • NCT05858346 · 264 participants · NA

    Comparing TBT to Disorder-Specific Psychotherapy in Veterans With Social Anxiety Disorder

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04101669, the US trial registry maintained by the National Library of Medicine. NCT04101669 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.